Bruno Carlos
Sangro Gómez-Acebo
Catedrático de Universidad
Harvard Medical School
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Harvard Medical School (1)
2022
-
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3537-3545